Cellectar reports financial results for second quarter 2022

Florham park, n.j., aug. 05, 2022 (globe newswire) -- cellectar biosciences, inc. (nasdaq: clrb), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced financial results for the second quarter ended june 30, 2022.
CLRB Ratings Summary
CLRB Quant Ranking